GLP-4
The metabolic advantage of injection — without the needle.
GLP-1 receptor agonists work. The delivery method — daily subcutaneous injection with significant nausea and muscle loss — is not a sustainable protocol for most people. GLP-4 delivers targeted metabolic compounds through transmucosal absorption, bypassing digestion entirely.
Metabolic energy
Mitochondrial-level energy regulation. Compounds targeting the energy substrate cycle for sustained cellular output rather than stimulant-driven peaks.
Insulin sensitivity
Glucose transporter modulation and insulin signaling pathway support. Targets post-meal glucose dynamics that drive fat storage and energy crashes.
Sirtuin activation
SIRT1 and SIRT3 pathway support — the same longevity mechanisms that caloric restriction activates. Metabolic efficiency at the gene expression level.
Lipolysis support
Targeted fat mobilization pathway activation. Supports the biochemical cascade that releases stored fatty acids for energy, replicating part of what injectable GLP-1 agonists achieve.
GLP-4 delivers complementary metabolic compounds through a non-injection route. It is not a pharmaceutical substitute — it is a precision metabolic support protocol for individuals who want the mechanism without the clinical intervention.
None. The compounds in GLP-4 support metabolic pathways through different mechanisms that do not produce nausea, vomiting, or the muscle catabolism associated with aggressive caloric restriction protocols.
Equivalent bioavailability through both routes. Nasal is faster for acute application. Sublingual allows for more controlled dosing. Both bypass first-pass metabolism.